Advisor Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Advisor Group’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$5K	Sell	1,000 -2,000	-67%	-$7.49K	﹤0.01%	4678
2019 Q3	$9K	Buy	3,000 +2,000	+200%	+$6.66K	﹤0.01%	4400
2019 Q2	$4K	Hold	1,000	–	–	﹤0.01%	4772
2019 Q1	$4K	Hold	1,000	–	–	﹤0.01%	4780
2018 Q4	$3K	Hold	1,000	–	–	﹤0.01%	4724
2018 Q3	$5K	Hold	1,000	–	–	﹤0.01%	4602
2018 Q2	$7K	Buy	+1,000	New	+$7.25K	﹤0.01%	4253

Other funds holding ORMP

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RPC

Rossmore Private Capital Glastonbury, Connecticut $1.24B AUM 28.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Advisor Group's ORMP Position: Q4 2019 in Review

Advisor Group reduced its Oramed Pharmaceuticals (ORMP) stake by 67% in Q4 2019, selling an estimated $7.49K and leaving 1,000 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4678.

Advisor Group first reported a position in ORMP in Q2 2018 and has held it in 7 quarters since. The position peaked at $9K in Q3 2019. 30 funds tracked by Wall St. Rank hold ORMP as of Q4 2019.

Advisor Group held 1,000 shares of Oramed Pharmaceuticals worth $5K as of Q4 2019.
Advisor Group sold 2,000 Oramed Pharmaceuticals shares in Q4 2019, an estimated $7.49K.
Oramed Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4678 holding.
Advisor Group first reported a position in Oramed Pharmaceuticals in Q2 2018 and has held it in 7 quarters since.
Advisor Group's Oramed Pharmaceuticals position peaked at $9K in Q3 2019.
30 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.